To provide a comprehensive analysis of anatomic patterns of recurrence following external beam radiotherapy (EBRT) for localized prostate cancer (PC) patients.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
This retrospective analysis included 2694 patients with localized PC receiving definitive dose-escalated EBRT from 1991 to 2008. First-recurrence sites (FRS) were defined as initial sites of clinically detected recurrence (CDR) and any subsequent CDR within 3 months. Anatomic recurrence patterns were classified as local (prostate/seminal vesicles only), lymphotropic (lymph nodes [LN] only), and osteotropic (bones only) for patients with disease confined solely to these respective sites for at least 2 years from initial CDR.
Prostate was the most common FRS for all risk groups (8-year cumulative incidence, 3.5%, 9.8%, and 14.6% for low-, intermediate-, and high-risk patients, respectively). Eight-year risk of isolated pelvic LN relapse as FRS was 0%, 1.0%, and 3.3%, respectively. For the 474 patients experiencing CDR, the most common FRSs were local (55.3%), bones (33.5%), pelvic LN (21.3%), and abdominal LN (9.1%). Patients displayed unique relapse distributions, including local (41.6%), lymphotropic (9.7%), osteotropic (20.3%), and multiorgan/visceral (28.5%) patterns. Anatomic recurrence pattern was the strongest predictor for PCSM in a multivariate analysis of CDR patients.
The most common FRS after dose-escalated EBRT for PC is within the prostate and SV for all risk groups. By contrast, patients treated without elective pelvic LN irradiation have a relatively low risk of isolated pelvic LN relapse. Recurrence patterns displayed a tropism for specific anatomic distributions, with divergent prognoses, suggesting underlying biological differences amongst tumors.
J Urol. 2015 Jul 9. pii: S0022-5347(15)04327-X. doi: 10.1016/j.juro.2015.06.100. [Epub ahead of print]
Zumsteg ZS1, Spratt DE1, Romesser PB1, Pei X1, Zhang Z1, Kollmeier M1, McBride S1, Yamada Y1, Zelefsky MJ2.
1 Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY.
2 Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY.